Table 4 Most active compounds in vitro from the Pfizer STLAR library
From: Repositioning: the fast track to new anti-malarial medicines?
Compound | Class (therapeutic area) | EC503D7 (μM) | EC50K1 (μM) |
|---|---|---|---|
UK-112,214 | Dual platelet activating factor/histamine H1 receptor antagonist (allergic rhinitis) | 0.55 (0.45, 0.65) | 0.6 (NA) |
CP-631992 | Neuropeptide Y5 receptor antagonist (obesity) | 0.7 (NA) | 0.40 (0.2, 0.6) |
CE-245677 | TIE2 tyrosine kinase inhibitor (oncology) | 1.1 (NA) | 0.8 (NA) |
CJ-0231112 | Bradykinin B2 receptor antagonist (pain) | 0.65 (0.36, 0.94) | 0.4 (NA) |
AG-024322 | CDK1/2/4/5 inhibitor (oncology) | 0.7 (0.11, 1.29) | 0.4 (NA) |